Literature DB >> 9882389

Systemic antibodies can inhibit mouse mammary tumor virus-driven superantigen response in mucosa-associated lymphoid tissues.

D Velin1, G Fotopoulos, J P Kraehenbuhl, H Acha-Orbea.   

Abstract

Many mucosal pathogens invade the host by initially infecting the organized mucosa-associated lymphoid tissue (o-MALT) such as Peyer's patches or nasal cavity-associated lymphoid tissue (NALT) before spreading systemically. There is no clear demonstration that serum antibodies can prevent infections in o-MALT. We have tested this possibility by using the mouse mammary tumor virus (MMTV) as a model system. In peripheral lymph nodes or in Peyer's patches or NALT, MMTV initially infects B lymphocytes, which as a consequence express a superantigen (SAg) activity. The SAg molecule induces the local activation of a subset of T cells within 6 days after MMTV infection. We report that similar levels of anti-SAg antibody (immunoglobulin G) in serum were potent inhibitors of the SAg-induced T-cell response both in peripheral lymph nodes and in Peyer's patches or NALT. This result clearly demonstrates that systemic antibodies can gain access to Peyer's patches or NALT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9882389      PMCID: PMC104008     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

Review 1.  Molecular and cellular basis of immune protection of mucosal surfaces.

Authors:  J P Kraehenbuhl; M R Neutra
Journal:  Physiol Rev       Date:  1992-10       Impact factor: 37.312

2.  Vaccine immunity.

Authors:  P C Beverley
Journal:  Immunol Today       Date:  1997-09

3.  Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission.

Authors:  W Held; G A Waanders; A N Shakhov; L Scarpellino; H Acha-Orbea; H R MacDonald
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

4.  Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes.

Authors:  A D Badley; J A McElhinny; P J Leibson; D H Lynch; M R Alderson; C V Paya
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  THE MILK-INFLUENCE OF BREAST TUMORS IN MICE.

Authors:  J J Bittner
Journal:  Science       Date:  1942-05-01       Impact factor: 47.728

6.  Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins.

Authors:  R Weltzin; P Lucia-Jandris; P Michetti; B N Fields; J P Kraehenbuhl; M R Neutra
Journal:  J Cell Biol       Date:  1989-05       Impact factor: 10.539

7.  Positive selection determines T cell receptor V beta 14 gene usage by CD8+ T cells.

Authors:  N S Liao; J Maltzman; D H Raulet
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

8.  An exogenous mouse mammary tumor virus with properties of Mls-1a (Mtv-7).

Authors:  W Held; A N Shakhov; G Waanders; L Scarpellino; R Luethy; J P Kraehenbuhl; H R MacDonald; H Acha-Orbea
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

9.  Retroviral infection of neonatal Peyer's patch lymphocytes: the mouse mammary tumor virus model.

Authors:  O Karapetian; A N Shakhov; J P Kraehenbuhl; H Acha-Orbea
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  Inhibition of mouse mammary tumor virus-induced T cell responses in vivo by antibodies to an open reading frame protein.

Authors:  H Acha-Orbea; L Scarpellino; A N Shakhov; W Held; H R MacDonald
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  2 in total

1.  Identification of a transcytosis epitope on staphylococcal enterotoxins.

Authors:  Jeffrey W Shupp; Marti Jett; Carol H Pontzer
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

2.  Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.

Authors:  M Mpandi; L A Otten; C Lavanchy; H Acha-Orbea; D Finke
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.